Trial Profile
PDL-1 Inhibition With Avelumab and Concurrent Second-generation ADT in African Americans With Castrate-resistant Metastatic Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Abiraterone; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Mar 2023 Results exploring the efficacy of the PD-L1 inhibitor avelumab in Black men with metastatic castrate-resistant prostate cancer (mCRPC) progressing after abiraterone or enzalutamide, published in the Oncologist
- 17 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 13 Feb 2021 Results exploring the efficacy of PD-L1 inhibition in African Americans men presented at the 2021 Genitourinary Cancers Symposium